Navigation Links
Histogen Welcomes Dr. Hyma Gollamudi as Chief Business Officer
Date:12/3/2008

Regenerative Medicine Company Poised for Business Growth

San Diego, CA (PRWEB) December 3, 2008 -- Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn fibroblasts, announced today that Dr. Hyma Gollamudi has joined the Company as Chief Business Officer. Gollamudi's business and product development expertise will be invaluable as Histogen begins seeking strategic alliances nationally and internationally.

"With our early-stage product launches underway, and exciting projects coming quickly down the pipeline, Histogen is increasingly examining relationships with companies, physicians and investors," said Dr. Gail Naughton, Histogen CEO and Chairman of the Board. "I am excited to welcome Hyma Gollamudi to Histogen, and look forward to seeing the Company's business development and strategic planning efforts flourish through her oversight and experience."

Dr. Gollamudi brings more than 10 years of experience from the healthcare and financial industries to Histogen. Most recently, she served as a Product Director in the healthcare division of Fair Isaac Corporation, a leading provider of analytics and decision management technology. In this position, Dr. Gollamudi oversaw alliances and partnerships and grew the Company's government (Medicare and Medicaid) and commercial business through dedicated attention to client relationships and client managements.

Dr. Gollamudi has authored a number of papers, presented at various healthcare conferences and working groups, and is the co-inventor on two patents. She holds a doctorate in Agricultural Economics from the Ohio State University.

"Histogen's broad range of product applications from a single technology platform is intriguing, and offers almost limitless opportunities in markets from research tools to cosmetics," said Gollamudi. "I am excited to work toward forming alliances, navigating products through reimbursement hurdles, and contributing to the Company's success in various markets."

Through the Company's proprietary bioreactor technology, Histogen is uniquely capable of simulating the embryonic environment, creating products that are embryonic in nature without containing embryonic stem cells or animal components. From two product families - ExCeltrixTM, Histogen's insoluble human Extracellular Matrix (ECM), and ReGenicaTM, Histogen's proprietary liquid complex - the Company has created a product portfolio which includes applications from stem cell culturing to skin care, tissue regeneration to hair regrowth.

About Histogen
Histogen, launched in 2007, seeks to redefine regenerative medicine by developing a series of high-value products that do not contain embryonic stem cells or animal components. Through Histogen's proprietary bioreactors that mimic the embryonic environment, newborn fibroblasts are encouraged to naturally produce the vital proteins and growth factors from which the Company has developed its rich product portfolio. Histogen recently launched its first product - BioNuesisTM Human Stem Cell Culturing Kits - and announced the creation of its cosmeceutical venture - Histogen Aesthetics. For more information, please visit www.histogeninc.com.

###

Read the full story at http://www.prweb.com/releases/Histogen/Gollamudi/prweb1697874.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related biology technology :

1. Histogen Announces Start of Hair Regrowth Clinical Evaluation
2. Dr. Gail Naughton Speaks on Histogen's Business Plan and the Rise of Bioaesthetic Medicine during Commercial Translation of Regenerative Medicine
3. Recognized Dermatology Expert Dr. Zoe Draelos Joins Histogen Scientific Advisory Board
4. Histogen Aesthetics is Created to Address Growing Medical Aesthetics Market
5. Histogen Launches BioNuesis, the Only All-Human Stem Cell Culturing Kit
6. Trusted LASIK Surgeons Welcomes LASIK Expert Michael Raizman of Boston to its Unique LASIK Directory
7. South Africas Minister of Minerals and Energy Welcomes Denham Capital Investment in BioTherm Energy to Develop Power Generation Business
8. Vineland Welcomes Dr. Isabelle Lesschaeve as Research Chair, Sensory and Consumer Sciences
9. Sigma-Aldrich Welcomes Memorial Sloan-Kettering Cancer Center to the RNAi Partnership Program
10. Vineland Welcomes Dr. Daryl Somers as Research Chair, Molecular Breeding and Biotechnology
11. Spring Point Project Welcomes Second Generation Medical-Grade Piglets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... One Million Solutions in Health ... million in investment towards 15+ TEC Validation Projects™. As a pre-competitive consortium, ... in drug safety assessment, for the industry as a whole. , Through the ...
(Date:1/16/2017)... ... January 16, 2017 , ... Appellate Court of New ... the appeal filed by India-based Dishman Pharmaceutical & Chemical Ltd. company (DPCL) for ... one of its Dishman Group’s 100% wholly owned New Jersey-based subsidiary Dishman USA ...
(Date:1/14/2017)... -- The Alliance for Safe Biologic Medicines (ASBM) today issued ... guidance on biologic naming: We commend ... importance of distinct naming for all biologics, including biosimilars. ... will bring to patients, including new treatment options and ... the Guidance dealing with suffix design remains at odds ...
(Date:1/13/2017)... Island, NY (PRWEB) , ... January 13, 2017 ... ... teamed up with several companies to offer its customers three new solutions for ... probe would come in handy if a customer has an oddly-shaped sample that ...
Breaking Biology Technology:
(Date:12/16/2016)... , Dec. 16, 2016 The global wearable medical device ... billion by 2021 from USD 5.31 billion in 2016, at a ... ... driven by technological advancements in medical devices, launch of a growing ... for wireless connectivity among healthcare providers, and increasing focus on physical ...
(Date:12/15/2016)... 2016   WaferGen Bio-systems, Inc. (NASDAQ: ... announced today that on December 13, 2016, it received ... Nasdaq Stock Market LLC which acknowledged that, as of ... common stock had been at $1.00 or greater for ... with Listing Rule 5550(a)(2) of the Nasdaq Stock Market. ...
(Date:12/15/2016)... Dec. 15, 2016 Advancements in ... health wellness and wellbeing (HWW), and security ... three new passenger vehicles begin to feature ... recognition, heart beat monitoring, brain wave monitoring, ... monitoring, and pulse detection. These will be ...
Breaking Biology News(10 mins):